The pharmacology and therapeutic applications of monoclonal antibodies
MS Castelli, P McGonigle… - Pharmacology research & …, 2019 - Wiley Online Library
Monoclonal antibodies (mAbs) have emerged as a major class of therapeutic agents on the
market. To date, approximately 80 mAbs have been granted marketing approval. In 2018, 12 …
market. To date, approximately 80 mAbs have been granted marketing approval. In 2018, 12 …
Targeting B cells and plasma cells in autoimmune diseases
K Hofmann, AK Clauder, RA Manz - Frontiers in immunology, 2018 - frontiersin.org
Success with B cell depletion using rituximab has proven the concept that B lineage cells
represent a valid target for the treatment of autoimmune diseases, and has promoted the …
represent a valid target for the treatment of autoimmune diseases, and has promoted the …
Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development
M Ovacik, K Lin - Clinical and translational science, 2018 - Wiley Online Library
The tutorial introduces the readers to the fundamentals of antibody pharmacokinetics (PK) in
the context of drug development. Topics covered include an overview of antibody …
the context of drug development. Topics covered include an overview of antibody …
Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
Several novel anti-CD20 monoclonal antibodies are currently in development with the aim of
improving the treatment of B cell malignancies. Mutagenesis and epitope map** studies …
improving the treatment of B cell malignancies. Mutagenesis and epitope map** studies …
[HTML][HTML] Mechanisms of action of CD20 antibodies
Therapeutic monoclonal antibodies (mAbs) that target the CD20 antigen on B cells are
successfully used in the clinic for the depletion of B cells to treat various forms of cancer and …
successfully used in the clinic for the depletion of B cells to treat various forms of cancer and …
Biomedical imaging: principles, technologies, clinical aspects, contrast agents, limitations and future trends in nanomedicines
J Wallyn, N Anton, S Akram, TF Vandamme - Pharmaceutical research, 2019 - Springer
This review article presents the state-of-the-art in the major imaging modalities supplying
relevant information on patient health by real-time monitoring to establish an accurate …
relevant information on patient health by real-time monitoring to establish an accurate …
Tumor antigen–targeted, monoclonal antibody–based immunotherapy: clinical response, cellular immunity, and immunoescape
Purpose Tumor antigen (TA)–targeted monoclonal antibodies (mAb), rituximab,
trastuzumab, and cetuximab, are clinically effective for some advanced malignancies …
trastuzumab, and cetuximab, are clinically effective for some advanced malignancies …
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
SA Beers, RR French, HTC Chan… - Blood, The Journal …, 2010 - ashpublications.org
Rituximab, a monoclonal antibody that targets CD20 on B cells, is now central to the
treatment of a variety of malignant and autoimmune disorders. Despite this success, a …
treatment of a variety of malignant and autoimmune disorders. Despite this success, a …
Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going?
Therapeutic monoclonal antibodies (mAbs) have become one of the fastest growing classes
of drugs in recent years and are approved for the treatment of a wide range of indications …
of drugs in recent years and are approved for the treatment of a wide range of indications …
FcγR dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities
Given the widespread use of antibodies of the immunoglobulin G (IgG) class as cytotoxic,
immunomodulatory, and neutralizing agents in the therapy of malignant, infectious, and …
immunomodulatory, and neutralizing agents in the therapy of malignant, infectious, and …